Sai Life Sciences secures SBTi validation for near-term climate targets

Core Insights - Sai Life Sciences Limited has received validation from the Science Based Targets initiative (SBTi) for its near-term greenhouse gas (GHG) emissions reduction targets, emphasizing its commitment to sustainability in the pharmaceutical value chain [1][2]. Sustainability Commitments - The company aims to reduce absolute scope 1 and 2 GHG emissions by 58.8% by FY2035 from a FY2024 base year [2]. - Additionally, it plans to cut scope 3 GHG emissions by 63.8% per INR value added within the same timeframe, covering various categories such as purchased goods and services, capital goods, and employee commuting [2]. Recent Achievements - Sai Life Sciences has made significant investments in its sustainability agenda, achieving 96% reliance on renewable energy in FY25 at its Bidar facility, which resulted in a reduction of 16,038 metric tons of CO₂ emissions [7]. - Currently, 54% of the company's total energy consumption comes from renewable sources, with a target of reaching 70% by FY27 and 80% by 2030 [7]. Strategic Partnerships - The company is collaborating with DHL GoGreen to reduce logistics-related emissions by 90% [7]. - It has also become the first India-headquartered company to join the Pharmaceutical Supply Chain Initiative (PSCI) [7]. Organizational Overview - Sai Life Sciences is a leading integrated contract research, development, and manufacturing organization (CRDMO) that collaborates with over 300 global pharmaceutical and biotech companies [4].